Viloxazine Under Review for ADHD Treatment in Adults
The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults...Viloxazine is currently marketed under the trade name Qelbree and is indicated for the treatment of ADHD in patients 6 to 17 years of age.
Other Articles in this Edition
Amino Acid Profile Differentiation Detected Among Children With ADHD
Link Discovered Between ADHD and Dementia Across Generations
ADHD and obesity are linked through genetics and pregnancy weight, study finds
What to know about ADHD and Zoom meetings
‘Munchausen by Internet’ and the dangers of self-diagnosing mental health issues on TikTok